Benzinga·Aug 14, 2026
MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'MDxHealth SA (NASDAQ:MDXH) stock skyrocketed on Friday after the diagnostic company reported mixed quarterly earnings.
MDxHealth faces a precarious financial outlook characterized by a negative $12.1 million equity position and a reliance on debt financing to fund ongoing operations. While revenue grew 13.8% in 2025Q4, the company struggles to achieve operating leverage, evide...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.18+6.9% vs -$0.19 | $27M+4.1% vs $26M |
Q2 2026 May 13, 2026 | -$0.19-46.2% vs -$0.13 | $24M-22.6% vs $31M |
Q1 2026 Feb 26, 2026 | -$0.17-30.8% vs -$0.13 | $30M-2.7% vs $30M |
Q4 2025 Nov 12, 2025 | -$0.16-33.3% vs -$0.12 | $27M+4.3% vs $26M |
MDxHealth SA (NASDAQ:MDXH) stock skyrocketed on Friday after the diagnostic company reported mixed quarterly earnings.
MDxHealth SA (MDXH) Q2 2026 Earnings Call Transcript
MDxHealth SA (MDXH) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.15 per share a year ago.
Second quarter r evenue gr owth of 1 6 % to $ 2 7 . 2 million Conference call with Q&A today at 4 : 3 0 PM EST / 22 : 30 CET
Benchmark MDXH against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for MDxHealth S.A. (MDXH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.57 | $29.33M | -0.85 | 19.8% | -31.07% | -2440.41% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $45.81 | $3.66B | 55.87 | 16.01% | 20.37% | 8.64% | — | |
| $410.35 | $58.77B | -269.97 | 35.9% | -7.11% | -11.73% | — | |
| $10.77 | $734.42M | -0.65 | -1.89% | -39.2% | -55.3% | — | |
| $273.04 | $41.31B | 50.10 | -0.78% | 18.36% | 31.08% | — |
MDxHealth S.A. (MDXH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when MDXH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDxHealth S.A. (MDXH) stock FAQ — growth, dividends, profitability & financials explained
MDxHealth S.A. (MDXH) reported $156.5M in revenue for fiscal year 2025. This represents a 29661% increase from $0.5M in 2004.
MDxHealth S.A. (MDXH) grew revenue by 19.8% over the past year. This is strong growth.
MDxHealth S.A. (MDXH) reported a net loss of $55.7M for fiscal year 2025.
MDxHealth S.A. (MDXH) has a return on equity (ROE) of -2440.4%. Negative ROE indicates the company is unprofitable.
MDxHealth S.A. (MDXH) had negative free cash flow of $16.7M in fiscal year 2025, likely due to heavy capital investments.
